Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma

NEJM Evid. 2023 Oct;2(10):EVIDoa2300135. doi: 10.1056/EVIDoa2300135. Epub 2023 Sep 20.

Abstract

Tezepelumab and Mucus Plugs in Patients with AsthmaMucus plugs in airways of asthma patients are associated with airway obstruction and the activity of inflammatory cytokines. This article reports prespecified and post hoc analyses of the effect of tezepelumab treatment on mucus plugs identified by computed tomography imaging in patients with moderate-to-severe asthma. At baseline, mucus plug scores correlated positively with levels of inflammatory biomarkers and negatively with lung function measures. Patients treated with tezepelumab had resolution of more mucus plugs than patients taking placebo.

Publication types

  • Clinical Trial

MeSH terms

  • Airway Obstruction* / complications
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / complications
  • Humans
  • Mucus

Substances

  • Antibodies, Monoclonal, Humanized
  • tezepelumab